Effects of TAK-442, a direct factor XA inhibitor, and fondaparinux on platelet-associated prothrombinase in the balloon injured artery of rats

被引：0
|
作者：
Konishi, N. [1 ]
Katsuhiko, H. [1 ]
Imaeda, Y. [2 ]
Fujimoto, T. [2 ]
Kubo, K. [3 ]
Kawamura, M. [4 ]
机构：
[1] Takeda Pharmaceut Co, Pharmacol Res Labs 1, Osaka, Japan
[2] Takeda Pharmaceut Co, Med Chem Labs, Osaka, Japan
[3] Takeda Pharmaceut Co, Strateg Res Planning, Osaka, Japan
[4] Takeda Global Reaserch & Dev Ctr, TPC Liaison, Lake Forest, IL USA
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2009年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PP-WE-398
引用
收藏
页码：759 / 759
页数：1
相关论文
共 42 条
  • [31] Effects of combining YM150, an oral direct factor Xa inhibitor, with antiplatelet agents in rats
    Twatsuki, Yoshiyuki
    Sakata, Chinatsu
    Moritani, Yumiko
    Kaku, Seiji
    Sasamata, Masao
    Seki, Nobuo
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2011, 115 : 106P - 106P
  • [32] Anticoagulant and anti-platelet effects are maintained following coadministration of otamixaban, a direct factor Xa inhibitor, and acetylsalicylic acid
    Hinder, M
    Frick, A
    Rosenburg, R
    Hesse, G
    Ozoux, ML
    Laux, V
    Scholtz, H
    Gebauer, A
    Paccaly, A
    THROMBOSIS AND HAEMOSTASIS, 2006, 95 (02) : 224 - 228
  • [33] TAK-442, a novel oral direct factor Xa inhibitor does not inhibit CYP3A4, CYP1A2, CYP2C9 and CYP2D6 enzyme activity - Assessment using the Indiana cocktail approach
    Stringer, Fran
    Kupfer, Stuart
    Cao, Charlie
    Scott, Graham
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 70 (02) : 304 - 304
  • [34] The direct factor Xa inhibitor apixaban produces broad antithrombotic activity with limited effects on bleeding time in rats
    Schumacher, William A.
    Bostwick, Jeffrey S.
    Stewart, Anne B.
    Steinbacher, Thomas E.
    Pinto, Donald J.
    Wong, Pancras C.
    BLOOD, 2007, 110 (11) : 69B - 69B
  • [35] Comparative Effects of the Direct Factor Xa Inhibitor, Apixaban, and the Direct Inhibitors of Factor VIIa, XIa and Thrombin on Tissue Factor-Induced Human Platelet Aggregation.
    Jiang, Xiaosui
    Wong, Pancras C.
    BLOOD, 2008, 112 (11) : 704 - 705
  • [36] Rivaroxaban, a novel, oral, direct Factor Xa inhibitor, enhanced the antithrombotic effects of clopidogrel and acetylsalicylic acid in rats
    Perzborn, E.
    Fischer, E.
    Lange, U.
    EUROPEAN HEART JOURNAL, 2007, 28 : 189 - 189
  • [37] Effects of dabigatran, a direct thrombin inhibitor, as compared to the direct factor Xa inhibitors, rivaroxaban and apixaban, on tissue factor-induced human platelet aggregation in platelet rich plasma.
    van Ryn, Joanne
    Kink-Eiband, Monika
    Hauel, Norbert
    Priepke, Henning
    Wienen, Wolfgang
    BLOOD, 2007, 110 (11) : 558A - 558A
  • [38] Anticoagulant and anti-platelet effects are maintained following coadministration of otamixaban, a direct factor Xa inhibitor, with tirofiban in healthy volunteers
    Hinder, M
    Paccaly, A
    Frick, A
    Shukla, U
    Simcox, K
    Miller, B
    Gebauer, A
    THROMBOSIS AND HAEMOSTASIS, 2005, 93 (04) : 794 - 795
  • [39] The effects of warfarin and edoxaban, an oral direct factor Xa inhibitor, on gammacarboxylated (Gla-osteocalcin) and undercarboxylated osteocalcin (uc-osteocalcin) in rats
    Morishima, Yoshiyuki
    Kamisato, Chikako
    Honda, Yuko
    Furugohri, Taketoshi
    Shibano, Toshiro
    THROMBOSIS RESEARCH, 2013, 131 (01) : 59 - 63
  • [40] Comparison of the effects of heparin and the direct factor Xa inhibitor, rivaroxaban, on bone microstructure and metabolism in adult rats (vol 56, pg 477, 2016)
    Xia, Jingjun
    Zhang, Zhipeng
    Wang, Jialiang
    Zu, Jianing
    Wang, Nanxiang
    Wang, Duanyang
    CONNECTIVE TISSUE RESEARCH, 2016, 57 (01) : 68 - 68
12345